What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call

Treace outlines $206M-$210M 2026 revenue range while targeting $700M TAM expansion (NASDAQ:TMCI)

Treace Medical Q3 2026 earnings: revenue guidance tightened, ASP pressure persists, but new product adoption and Q4 growth hopes stand out.

What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call

Treace Medical Concepts (NASDAQ:TMCI) reported a 4% decline in third-quarter revenue as a shift toward lower-priced products and lower bunion procedure kit sales offset growth in procedure volumes. The company narrowed its full-year revenue outlook and said it expects to return to growth in the four

Treace Medical (TMCI) Q3 2026 Earnings Call Transcript

Product mix shifted lower as adjusted EBITDA turned positive this quarter.

Treace Medical Concepts: Q3 Earnings Snapshot – WTOP News

PONTE VEDRA, Fla. (AP) — PONTE VEDRA, Fla. (AP) — Treace Medical Concepts Inc. (TMCI) on Friday reported a loss of $12.6 million in its third quarter. On a per

Treace Medical Concepts: Q3 Earnings Snapshot

PONTE VEDRA, Fla. (AP) — PONTE VEDRA, Fla. (AP) — Treace Medical Concepts Inc. (TMCI) on Friday reported a loss of $12.6 million in its third quarter.

Treace Medical Concepts Q3 Revenue Falls 3.8% to $48.3 Million

The medical device company’s GAAP loss was 19 cents per share, 6 cents better than estimates. Its net loss improved 23% to $12.6 million.